Moderna Pharmaceuticals said on Wednesday it would not issue the Hep B vaccine to players, coaches or trainers after the manufacturer had not been able to provide the vaccine’s safety and effectiveness data.
The company said in a statement that Moderna “has not been granted access to the vaccine manufacturing facilities in the United States” to meet the company’s standards.
Moderna has not said how many Hep B vaccinations it is prepared to offer players or trainers in 2017.
Moderno has said it is working with the NFL to find a solution.
ModernA has had trouble meeting the company.
In June, the company said it was unable to meet FDA standards for the vaccine, saying the manufacturer was not producing the required vaccines.
The vaccine has been a controversial issue for the NFL, which had been preparing for the 2018 season with a vaccine-for-all plan.
The league said it planned to reissue the vaccine to teams and players after it was clear Moderna could not meet the standards.
The NFL has said there is no reason to expect Moderna to stop issuing vaccines.
Modern A said it will resume production of Hep B shots on Tuesday.
The Hep B vaccination program has not been fully implemented for several years, and the FDA said in July it was concerned about the safety of the vaccine.
Modern a has had problems with manufacturing, safety and quality control of the HepB vaccine, the CDC said.
In 2014, the Hep A vaccine was pulled because it was too toxic for use.
The brand had received multiple recalls since that time, including one in 2016 after it accidentally contaminated the vaccine with a virus called coronavirus-1.